Screener
4D Molecular Therapeutics FDMT Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Deferred revenue | 360 | 360 |
| Operating lease liabilities, current portion | 5,486 | 5,592 |
| Total current liabilities | 43,404 | 43,985 |
| Deferred revenue, net of current portion | 2,125 | 745 |
| Derivative liability | 370 | 358 |
| Operating lease liabilities, long-term portion | 15,049 | 15,821 |
| Other liabilities | 121 | 138 |
| Total liabilities | 61,069 | 61,047 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's contract liabilities, non-current?
- 4D Molecular Therapeutics (FDMT) reported contract liabilities, non-current of $2.13M in Q1 2026.
- How has 4D Molecular Therapeutics's contract liabilities, non-current changed year-over-year?
- 4D Molecular Therapeutics's contract liabilities, non-current increased by 389.6% year-over-year, from $434K to $2.13M.
- What is the long-term trend for 4D Molecular Therapeutics's contract liabilities, non-current?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's contract liabilities, non-current has grown at a -43.7% compound annual growth rate (CAGR), from $13.23M to $745K.
Ask your AI about 4D Molecular Therapeutics's contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude